Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Hold at Zacks Research

Key Points

• Supernus Pharmaceuticals has been upgraded by Zacks Research from a "strong sell" to a "hold" rating, indicating a shift in analysts' outlook on the stock.
• The company's stocks were also rated "buy" by Wall Street Zen, and Supernus currently has an average rating of "Moderate Buy" with a consensus target price of $41.00.
• Insider trading activity includes CEO Jack A. Khattar selling 140,000 shares, reducing his ownership by nearly 12%, while several large investors have recently increased their stakes in the company.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Tuesday,Zacks.com reports.

A number of other research firms have also recently issued reports on SUPN. Cantor Fitzgerald raised their price objective on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $41.00.

Supernus Pharmaceuticals Trading Up 3.6%

Shares of SUPN traded up $1.56 during mid-day trading on Tuesday, reaching $44.88. The company's stock had a trading volume of 1,047,668 shares, compared to its average volume of 1,064,514. Supernus Pharmaceuticals has a 1-year low of $29.16 and a 1-year high of $45.01. The stock has a market cap of $2.52 billion, a P/E ratio of 39.03 and a beta of 0.74. The business has a 50-day simple moving average of $35.41 and a two-hundred day simple moving average of $33.69.

Insider Transactions at Supernus Pharmaceuticals

In other news, Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the transaction, the director owned 46,307 shares in the company, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 140,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This trade represents a 11.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,826 shares of company stock worth $6,424,773. Company insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in SUPN. LPL Financial LLC increased its stake in Supernus Pharmaceuticals by 18.9% during the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company's stock worth $461,000 after acquiring an additional 2,029 shares during the period. Wells Fargo & Company MN increased its stake in Supernus Pharmaceuticals by 14.4% during the 4th quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company's stock worth $2,287,000 after acquiring an additional 7,961 shares during the period. Envestnet Asset Management Inc. increased its stake in Supernus Pharmaceuticals by 6.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company's stock worth $2,169,000 after acquiring an additional 3,495 shares during the period. Bank of Montreal Can increased its stake in Supernus Pharmaceuticals by 6.6% during the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after acquiring an additional 473 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals during the 4th quarter worth $6,847,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.